Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.
2.

Unanswered questions about the 1918 influenza pandemic: origin, pathology, and the virus itself.

Oxford JS, Gill D.

Lancet Infect Dis. 2018 Nov;18(11):e348-e354. doi: 10.1016/S1473-3099(18)30359-1. Epub 2018 Jun 20. Review.

PMID:
29935779
3.

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.

Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D.

PLoS One. 2016 Dec 22;11(12):e0163089. doi: 10.1371/journal.pone.0163089. eCollection 2016.

4.

Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.

Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJ, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, Osterhaus AD, Knight A, Oxford JS, Lapini G, Cox R, Lambkin-Williams R.

PLoS One. 2014 May 21;9(5):e93761. doi: 10.1371/journal.pone.0093761. eCollection 2014.

5.

Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination.

Moss AJ, Gaughran FP, Karasu A, Gilbert AS, Mann AJ, Gelder CM, Oxford JS, Stephens HA, Lambkin-Williams R.

PLoS One. 2013 Aug 9;8(8):e71376. doi: 10.1371/journal.pone.0071376. eCollection 2013.

6.

Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals.

Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, Lambkin-Williams R, Oxford JS, McClain MT, Wilkinson T, Nicholson BP, Ginsburg GS, Devincenzo JP.

Antivir Ther. 2013;18(6):785-91. doi: 10.3851/IMP2629. Epub 2013 May 28.

PMID:
23714753
7.
8.

Clinical, scientific and ethnographic studies of influenza in quarantine.

Oxford JS, Oxford JR.

Expert Rev Vaccines. 2012 Aug;11(8):929-37.

PMID:
23002974
9.

Effectiveness of H1N1 vaccination in Scotland, UK.

Oxford JS.

Lancet Infect Dis. 2012 Sep;12(9):653-4. doi: 10.1016/S1473-3099(12)70154-8. Epub 2012 Jun 26. No abstract available.

PMID:
22738891
10.

Acute sore throat revisited: clinical and experimental evidence for the efficacy of over-the-counter AMC/DCBA throat lozenges.

Oxford JS, Leuwer M.

Int J Clin Pract. 2011 May;65(5):524-30. doi: 10.1111/j.1742-1241.2011.02644.x. Review. No abstract available.

PMID:
21489076
11.

The end of the beginning: vaccines for the next 25 years.

Oxford JS.

Vaccine. 2008 Nov 18;26(49):6179-82. doi: 10.1016/j.vaccine.2008.07.106. Epub 2008 Sep 5.

PMID:
18775758
12.

Lack of evidence for complete resistance of peripheral blood mononuclear cells to HIV-1 and HIV-2 infection.

Al-Jabri AA, Lambkin R, Oxford JS.

Viral Immunol. 2008 Mar;21(1):83-90. doi: 10.1089/vim.2007.0092.

PMID:
18355126
13.

A plant-produced influenza subunit vaccine protects ferrets against virus challenge.

Mett V, Musiychuk K, Bi H, Farrance CE, Horsey A, Ugulava N, Shoji Y, de la Rosa P, Palmer GA, Rabindran S, Streatfield SJ, Boyers A, Russell M, Mann A, Lambkin R, Oxford JS, Schild GC, Yusibov V.

Influenza Other Respir Viruses. 2008 Jan;2(1):33-40. doi: 10.1111/j.1750-2659.2008.00037.x.

14.

Liposomal influenza vaccine: a viewpoint by John S. Oxford.

Oxford JS.

BioDrugs. 1999 Feb;11(2):145-6. No abstract available.

PMID:
18031124
15.

In vivo prophylactic activity of QR-435 against H3N2 influenza virus infection.

Oxford JS, Lambkin R, Guralnik M, Rosenbloom RA, Petteruti MP, Digian K, LeFante C.

Am J Ther. 2007 Sep-Oct;14(5):462-8.

PMID:
17890936
16.

Preclinical in vitro activity of QR-435 against influenza A virus as a virucide and in paper masks for prevention of viral transmission.

Oxford JS, Lambkin R, Guralnik M, Rosenbloom RA, Petteruti MP, Digian K, Lefante C.

Am J Ther. 2007 Sep-Oct;14(5):455-61.

PMID:
17890935
17.

Antivirals for the treatment and prevention of epidemic and pandemic influenza.

Oxford JS.

Influenza Other Respir Viruses. 2007 Jan;1(1):27-34. doi: 10.1111/j.1750-2659.2006.00006.x. Review.

18.

Scientific lessons from the first influenza pandemic of the 20th century.

Oxford JS, Lambkin R, Elliot A, Daniels R, Sefton A, Gill D.

Vaccine. 2006 Nov 10;24(44-46):6742-6. Epub 2006 Jun 16.

PMID:
17069939
19.

Functional and antigenic analyses of the 1918 influenza virus haemagglutinin using a recombinant vaccinia virus expression system.

Elliot AJ, Steinhauer DA, Daniels RS, Oxford JS.

Virus Res. 2006 Dec;122(1-2):11-9. Epub 2006 Aug 9.

PMID:
16904219
20.

Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection.

Mann A, Marriott AC, Balasingam S, Lambkin R, Oxford JS, Dimmock NJ.

Vaccine. 2006 May 15;24(20):4290-6. Epub 2006 Mar 20.

PMID:
16621180
21.

Influenza is now a preventable disease.

Oxford JS, Lambkin R.

Int J Antimicrob Agents. 2006 Apr;27(4):271-3. Epub 2006 Mar 27. Review.

PMID:
16564681
22.

A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines.

Oxford JS, Manuguerra C, Kistner O, Linde A, Kunze M, Lange W, Schweiger B, Spala G, Rebelo de Andrade H, Pérez Breña PR, Beytout J, Brydak L, Caraffa de Stefano D, Hungnes O, Kyncl J, Montomoli E, Gil de Miguel A, Vranckx R, Osterhaus A.

Vaccine. 2005 Nov 16;23(46-47):5440-9.

PMID:
16168526
23.

Zanamivir (Glaxo Wellcome).

Oxford JS.

IDrugs. 2000 Apr;3(4):447-59.

PMID:
16100701
24.

A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV.

Oxford JS, Lambkin R, Gibb I, Balasingam S, Chan C, Catchpole A.

Antivir Chem Chemother. 2005;16(2):129-34.

PMID:
15889535
25.

Preparing for the first influenza pandemic of the 21st century.

Oxford JS.

Lancet Infect Dis. 2005 Mar;5(3):129-31. No abstract available.

PMID:
15766642
26.

Would you volunteer to be quarantined and infected with influenza virus?

Oxford JS, Gelder C, Lambkin R.

Expert Rev Anti Infect Ther. 2005 Feb;3(1):1-2. No abstract available.

PMID:
15757450
27.

New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.

Oxford JS, Balasingam S, Chan C, Catchpole A, Lambkin R.

Antivir Chem Chemother. 2005;16(1):13-21. Review.

PMID:
15739618
29.

A designer drug against influenza: the NA inhibitor oseltamivir (Tamiflu).

Oxford JS, Mann A, Lambkin R.

Expert Rev Anti Infect Ther. 2003 Aug;1(2):337-42. Review.

PMID:
15482128
30.

Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.

Lambkin R, Oxford JS, Bossuyt S, Mann A, Metcalfe IC, Herzog C, Viret JF, Glück R.

Vaccine. 2004 Oct 22;22(31-32):4390-6.

PMID:
15474733
31.

Immunogold electron microscopy recognizes prion protein-associated particles prepared from scrapie-infected mouse brain.

Dourmashkin RR, Oxford JS, Bountiff L.

J Neuropathol Exp Neurol. 2004 Jan;63(1):32-42.

PMID:
14748559
32.

1918 influenza pandemic caused by highly conserved viruses with two receptor-binding variants.

Reid AH, Janczewski TA, Lourens RM, Elliot AJ, Daniels RS, Berry CL, Oxford JS, Taubenberger JK.

Emerg Infect Dis. 2003 Oct;9(10):1249-53. No abstract available.

33.

A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus.

Oxford JS, Bossuyt S, Lambkin R.

Immunology. 2003 Jul;109(3):326-8. Review. No abstract available.

34.

Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine.

Oxford JS, Al-Jabri AA, Lambkin R, Palache AM, Fleming DM.

Vaccine. 2003 Jun 20;21(21-22):2743-6.

PMID:
12798612
35.
36.

Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.

Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P, Lambkin R.

Clin Microbiol Infect. 2003 Jan;9(1):1-14. Review.

38.

New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors.

Oxford JS, Novelli P, Sefton A, Lambkin R.

Antivir Chem Chemother. 2002 Jul;13(4):205-17. Review.

PMID:
12495208
39.

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA.

Antiviral Res. 2002 Aug;55(2):307-17.

PMID:
12103431
40.

Influenza A: a threatening virus with two faces.

Oxford JS.

Biologist (London). 2002 Apr;49(2):63-7.

PMID:
11932503
41.

World War I may have allowed the emergence of "Spanish" influenza.

Oxford JS, Sefton A, Jackson R, Innes W, Daniels RS, Johnson NP.

Lancet Infect Dis. 2002 Feb;2(2):111-4.

PMID:
11901642
42.

The so-called Great Spanish Influenza Pandemic of 1918 may have originated in France in 1916.

Oxford JS.

Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1857-9. Review.

43.

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.

Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS; Oseltamivir Post Exposure Prophylaxis Investigator Group.

JAMA. 2001 Feb 14;285(6):748-54.

PMID:
11176912
44.

Influenza virus infection in the second and third trimesters of pregnancy: a clinical and seroepidemiological study.

Irving WL, James DK, Stephenson T, Laing P, Jameson C, Oxford JS, Chakraverty P, Brown DW, Boon AC, Zambon MC.

BJOG. 2000 Oct;107(10):1282-9.

45.

In vitro anti-HIV-1 virucidal activity of tyrosine-conjugated tri- and dihydroxy bile salt derivatives.

Al-Jabri AA, Wigg MD, Elias E, Lambkin R, Mills CO, Oxford JS.

J Antimicrob Chemother. 2000 May;45(5):617-21.

PMID:
10797083
46.

Rapid antibody response to influenza vaccination in "at risk" groups.

Lambkin R, Oxford JS, Biao L, Al-Jabri A, Fleming D.

Vaccine. 2000 Apr 28;18(21):2307-11.

PMID:
10717351
47.
48.

Ground penetrating radar surveys to locate 1918 Spanish flu victims in permafrost.

Davis JL, Heginbottom JA, Annan AP, Daniels RS, Berdal BP, Bergan T, Duncan KE, Lewin PK, Oxford JS, Roberts N, Skehel JJ, Smith CR.

J Forensic Sci. 2000 Jan;45(1):68-76.

PMID:
10641921
49.

Anti-human immunodeficiency virus activity of a new immunosuppressant drug called stepronin.

de Giorgi L, Habeshaw JA, Broadhurst K, Carminati P, Oxford JS.

Transplant Proc. 1999 Dec;31(8):3257. No abstract available.

PMID:
10616467
50.

Who's that lady?

Oxford JS, Sefton A, Jackson R, Johnson NP, Daniels RS.

Nat Med. 1999 Dec;5(12):1351-2. No abstract available.

PMID:
10581070

Supplemental Content

Loading ...
Support Center